Ventripoint and Lishman Global Sign Non-binding Term Sheet Defining License for VMS+ Technology

(TheNewswire)

Toronto, Ontario – TheNewswire - July 11, 2025 –Ventripoint Diagnostics Ltd. (“Ventripoint” or the“Corporation”),(TSXV:VPT) is pleased to announce that it has signed a non-binding termsheet with Lishman Global Inc. outlining the exclusive ,non-transferable license of Ventripoint technology for use withinLishman’s echocardiography image platform in the People’s Republicof China including the Special Administrative Regions of Hong Kong andMacao (the “Territory”).

Previously, Lishman’s Chinese subsidiary had received CFDA approval and a Certificate of Production(CoP) from the CFDA in the People’s Republic of China forthe VMS+ product used foranalysis of the right ventricle (RV) only of the heart. The subsidiary has a GMP certifiedmanufacturing facility in China that is able to produce at a scalecapable of addressing the Chinese market.

Upon execution, the new license will enable
Lishman and its subsidiaries to fully integrate
VMS+ 4.0 within its cart-based and hybrid echocardiography platforms
and to market the technology within the Territory. The final license
will specify annual minimum volumes once CFDA approval has been
secured. Lishman has placed a purchase order for VMS+ components
needed to support the manufacture of systems sufficient to support
validation of the product and submission to CFDA.  Lishman has
committed to an investment into Ventripoint.

“We appreciate the ongoing commitment of our Chinese
partners to VMS+,” stated Hugh MacNaught, President and CEO.
 “Heart disease remains the number one healthcare issue in China
with nearly twice the rate of hospital admissions for cardiovascular
conditions than in North America.  China has a higher rate of use of
echocardiograms than in North America and is expected to benefit from
both the performance improvements inherent to VMS+ that enable greater
accuracy of echo studies and the ability of the system to work with
sparse data that should reduce the number of repeat studies. Upon CFDA
approval all 32,000 hospitals in China and its territories will gain
awareness of a 2D echocardiography system that generates volumetric
results with similar levels of accuracy to cMRI.”

“We are looking forward to working closely with
Ventripoint to integrate VMS+ within our platforms, secure CFDA
approval, and actively market our solution to the Chinese clinical
community” stated Paul Gibson, CTO of Lishman.

Pre-marketing efforts are underway in the Chinese
market with the objective of establishing a presence within each of
the 22 provinces plus the Special Administrative Regions within the
country. There are over 2,500 Tier 1 hospitals and a total of 32,000
hospitals, with over 1,000 new hospitals currently under
construction.

About Lishman Global.

Lishman Global was establish in 2012 to assist
companies to safely enter the Chinese Market. Our partnership model
allows foreign companies to navigate the complex network of regulatory
approvals and multi-level distribution channels common in the Chinese
medical device market.

About Ventripoint Diagnostics
Ltd.

Ventripoint has become an
industry leader in the application of AI (Artificial Intelligence) to
echocardiography. Ventripoint's VMS products are powered by its
proprietary knowledge-based reconstruction technology, which is the
result of a decade of development and provides accurate volumetric
cardiac measurements equivalent to MRI. This affordable, gold-standard
alternative allows cardiologists greater confidence in the management
of their patients. Providing better care to patients serves as a
springboard and basic standard for all of Ventripoint's products that
guide our future developments. In addition, VMS+ is versatile and can
be used with all ultrasound systems from any vendor supported by
regulatory market approvals in the U.S., Europe and Canada.

For further information, please
contact:

Hugh MacNaught

hmacnaught@ventripoint.com

604-671-4201

Neither the TSX Venture Exchange nor
its Regulation Services Provider (as that term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for the
adequacy or accuracy of this news release.

Forward Looking Statements

This news release contains forward-looking statements
and forward-looking information within the meaning of applicable
securities laws. The use of any of the words "expect",
"anticipate", "continue", "estimate",
"objective", "ongoing", "may",
"will", "project", "should",
"believe", "plans", "intends'' and similar
expressions are intended to identify forward-looking information or
statements. The forward-looking statements and information are based
on certain key expectations and assumptions made by the Corporation.
Although the Corporation believes that the expectations and
assumptions on which such forward-looking statements and information
are based are reasonable, undue reliance should not be placed on the
forward-looking statements and information because the Corporation can
give no assurance that they will prove to be correct.

Since forward-looking statements and information
address future events and conditions, by their very nature they
involve inherent risks and uncertainties. Actual results could differ
materially from those currently anticipated due to a number of factors
and risks. Factors which could materially affect such forward-looking
information are described in the risk factors in the Corporation's
most recent annual management's discussion and analysis that is
available on the Corporation's profile on SEDAR+ at www.sedarplus.ca. Readersare cautioned that the foregoing list of factors is not exhaustive.The forward-looking statements included in this news release areexpressly qualified by this cautionary statement. The forward-lookingstatements and information contained in this news release are made asof the date hereof and the Corporation undertakes no obligation toupdate publicly or revise any forward-looking statements orinformation, whether as a result of new information, future events orotherwise, unless so required by applicable securities laws.

Copyright (c) 2025 TheNewswire - All rights reserved.